Carcinoembryonic Antibody – Mouse Monoclonal

In IHC analysis, this CEA-specific antibody stains sections of colon tumour, with high levels of cell surface and cytoplasmic staining of malignant glands, and a more intense reaction in necrotic debris (Harwood et al, 1986). It does not cross-react with PMNs, erythrocytes or liver tissue. In an mouse model transplanted with the human colonic tumour MaWi, the weight of the xenograft has a profound effect on the uptake of a radiolabelled version of antibody (Pedley et al, 1987). In a xenograft tumour mouse model based on the adenocarcinoma cell line LS174T, both this antibody and its FAb have a significant effect on tumour growth when administered as radioimmunotherapeutic agents (Pedley et al, 1993). This antibody has also been shown to function as a radioimmunotherapy agent in a Phase I trial in gastrointestinal adenocarcinomas (Meyer et al, 2009), and has been shown in early clinical trials to target an enzyme capable of cleaving an inactive prodrug to release an active, cytotoxic drug to colorectal cancers (Bagshawe et al, 1991).